RNA-Binding Proteins and Non-coding RNAs in Cancer Therapeutic Resistance

Dear Colleagues,

The major determinants of cancer treatment failure and mortality include resistance to chemotherapy, targeted therapy, and immune therapy. The dynamic interaction of RNA-binding proteins (RBPs) with RNA elements modulates mRNA processing, stability, transport, and translation. Recent research has shown that RBPs affect the stability and localization of long noncoding RNAs (lncRNAs). RBPs may also bind circular RNAs (circRNAs) and serve crucial roles in the generation and degradation of circRNAs. RBPs are often dysregulated in human malignancies, and they affect the expression and activity of oncogenic and tumor-suppressor proteins, which influence the tumor's response to various treatments, including chemotherapy, targeted therapy, and immunotherapy. A comprehensive study of the interactions between RBPs and their non-coding RNA (ncRNA) targets is crucial for advancing our understanding of tumor biology and identifying possible novel anti-cancer treatment targets. We invite high-quality original research papers and review articles that provide new evidence and synthesize existing data to further our understanding of how RBPs and RNA molecules (particularly ncRNAs) interact to render cancers resistant to therapy.

These articles may contain, but are not limited to, the following subjects:

• Identification of genetic and epigenetic influences on RBP expression;
• The function of RBPs and ncRNAs in epithelial-to-mesenchymal transition (EMT), cancer stem cells (CSCs), cancer angiogenesis, cancer immunity, and cancer metabolism RBPs and their companion ncRNAs as essential indicators for cancer diagnosis and prognosis;
• Clarification of the molecular relationship between tumor RBPs and mRNAs or ncRNAs RBPs and their associated ncRNAs as prospective therapeutic alternatives for inhibiting metastasis and overcoming treatment resistance;
• Innovative approaches for finding and characterizing tumor-associated RBPs and their ncRNA targets.

Dr. Peixin Dong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• RNA-binding proteins
• non-coding RNAs
• lncRNAs
• circRNAs
• chemoresistance
• cancer metastasis
• EMT
• cancer stem cells
• cancer diagnosis
• cancer therapy